Cargando…

Health Services Utilization and Payments in Patients With Cancer Pain: A Comparison of Intrathecal Drug Delivery vs. Conventional Medical Management

INTRODUCTION: To compare health services utilization and payments for cancer patients who received an implantable intrathecal drug delivery (IDD) system, consisting of a pump and catheter, vs. conventional medical management (CMM) for the treatment of cancer‐related pain. METHODS: This retrospective...

Descripción completa

Detalles Bibliográficos
Autores principales: Stearns, Lisa J., Hinnenthal, Jennifer A., Hammond, Krisstin, Berryman, Eric, Janjan, Nora A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5066649/
https://www.ncbi.nlm.nih.gov/pubmed/26816205
http://dx.doi.org/10.1111/ner.12384
_version_ 1782460522688413696
author Stearns, Lisa J.
Hinnenthal, Jennifer A.
Hammond, Krisstin
Berryman, Eric
Janjan, Nora A.
author_facet Stearns, Lisa J.
Hinnenthal, Jennifer A.
Hammond, Krisstin
Berryman, Eric
Janjan, Nora A.
author_sort Stearns, Lisa J.
collection PubMed
description INTRODUCTION: To compare health services utilization and payments for cancer patients who received an implantable intrathecal drug delivery (IDD) system, consisting of a pump and catheter, vs. conventional medical management (CMM) for the treatment of cancer‐related pain. METHODS: This retrospective claims‐data analysis compared health services utilization and payments in a population of patients receiving either IDD or CMM for treatment of cancer pain. Patients were propensity score‐matched 1:1 based on characteristics including, but not limited to, age, gender, cancer type, comorbid conditions, and health care utilization and payments. RESULTS: From a sample of 142 IDD patients and 3188 CMM patients who met all inclusion/exclusion criteria, 73 matched pairs were obtained. In the year following implant, IDD patients had a consistent trend of lower medical utilization, and total payments that were $3195 lower compared to CMM. CONCLUSIONS: Despite the high initial cost of IDD, this analysis suggests that patients with IDD incur lower medical utilization and payments over the first year post‐implant. Further analysis comprised of a larger, longitudinal sample would contribute to health economics and outcomes research, and assist with future practice guideline development.
format Online
Article
Text
id pubmed-5066649
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-50666492016-11-01 Health Services Utilization and Payments in Patients With Cancer Pain: A Comparison of Intrathecal Drug Delivery vs. Conventional Medical Management Stearns, Lisa J. Hinnenthal, Jennifer A. Hammond, Krisstin Berryman, Eric Janjan, Nora A. Neuromodulation Intrathecal Drug Delivery Systems INTRODUCTION: To compare health services utilization and payments for cancer patients who received an implantable intrathecal drug delivery (IDD) system, consisting of a pump and catheter, vs. conventional medical management (CMM) for the treatment of cancer‐related pain. METHODS: This retrospective claims‐data analysis compared health services utilization and payments in a population of patients receiving either IDD or CMM for treatment of cancer pain. Patients were propensity score‐matched 1:1 based on characteristics including, but not limited to, age, gender, cancer type, comorbid conditions, and health care utilization and payments. RESULTS: From a sample of 142 IDD patients and 3188 CMM patients who met all inclusion/exclusion criteria, 73 matched pairs were obtained. In the year following implant, IDD patients had a consistent trend of lower medical utilization, and total payments that were $3195 lower compared to CMM. CONCLUSIONS: Despite the high initial cost of IDD, this analysis suggests that patients with IDD incur lower medical utilization and payments over the first year post‐implant. Further analysis comprised of a larger, longitudinal sample would contribute to health economics and outcomes research, and assist with future practice guideline development. John Wiley and Sons Inc. 2016-01-27 2016-02 /pmc/articles/PMC5066649/ /pubmed/26816205 http://dx.doi.org/10.1111/ner.12384 Text en © 2016 The Authors. Neuromodulation: Technology at the Neural Interface published by Wiley Periodicals, Inc. on behalf of International Neuromodulation Society This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Intrathecal Drug Delivery Systems
Stearns, Lisa J.
Hinnenthal, Jennifer A.
Hammond, Krisstin
Berryman, Eric
Janjan, Nora A.
Health Services Utilization and Payments in Patients With Cancer Pain: A Comparison of Intrathecal Drug Delivery vs. Conventional Medical Management
title Health Services Utilization and Payments in Patients With Cancer Pain: A Comparison of Intrathecal Drug Delivery vs. Conventional Medical Management
title_full Health Services Utilization and Payments in Patients With Cancer Pain: A Comparison of Intrathecal Drug Delivery vs. Conventional Medical Management
title_fullStr Health Services Utilization and Payments in Patients With Cancer Pain: A Comparison of Intrathecal Drug Delivery vs. Conventional Medical Management
title_full_unstemmed Health Services Utilization and Payments in Patients With Cancer Pain: A Comparison of Intrathecal Drug Delivery vs. Conventional Medical Management
title_short Health Services Utilization and Payments in Patients With Cancer Pain: A Comparison of Intrathecal Drug Delivery vs. Conventional Medical Management
title_sort health services utilization and payments in patients with cancer pain: a comparison of intrathecal drug delivery vs. conventional medical management
topic Intrathecal Drug Delivery Systems
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5066649/
https://www.ncbi.nlm.nih.gov/pubmed/26816205
http://dx.doi.org/10.1111/ner.12384
work_keys_str_mv AT stearnslisaj healthservicesutilizationandpaymentsinpatientswithcancerpainacomparisonofintrathecaldrugdeliveryvsconventionalmedicalmanagement
AT hinnenthaljennifera healthservicesutilizationandpaymentsinpatientswithcancerpainacomparisonofintrathecaldrugdeliveryvsconventionalmedicalmanagement
AT hammondkrisstin healthservicesutilizationandpaymentsinpatientswithcancerpainacomparisonofintrathecaldrugdeliveryvsconventionalmedicalmanagement
AT berrymaneric healthservicesutilizationandpaymentsinpatientswithcancerpainacomparisonofintrathecaldrugdeliveryvsconventionalmedicalmanagement
AT janjannoraa healthservicesutilizationandpaymentsinpatientswithcancerpainacomparisonofintrathecaldrugdeliveryvsconventionalmedicalmanagement